Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Development of EASY-Care, for brief standardized assessment of the health and care needs of older people; with latest information about cross-national acceptability.

Philip KE, Alizad V, Oates A, Donkin DB, Pitsillides C, Syddall SP, Philp I.

J Am Med Dir Assoc. 2014 Jan;15(1):42-6. doi: 10.1016/j.jamda.2013.09.007. Epub 2013 Oct 26.


Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.

Green LK, Syddall SP, Carlin KM, Bell GD, Guise CP, Mowday AM, Hay MP, Smaill JB, Patterson AV, Ackerley DF.

Mol Cancer. 2013 Jun 10;12:58. doi: 10.1186/1476-4598-12-58.


Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.

Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S, Holen I, Coleman RE.

Clin Cancer Res. 2013 May 15;19(10):2755-65. doi: 10.1158/1078-0432.CCR-12-3235. Epub 2013 Mar 20.


Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.

Prosser GA, Copp JN, Mowday AM, Guise CP, Syddall SP, Williams EM, Horvat CN, Swe PM, Ashoorzadeh A, Denny WA, Smaill JB, Patterson AV, Ackerley DF.

Biochem Pharmacol. 2013 Apr 15;85(8):1091-103. doi: 10.1016/j.bcp.2013.01.029. Epub 2013 Feb 8.


Combined therapies of bone disease with bisphosphonates.

Syddall SP, Ottewell PD, Holen I.

Curr Pharm Des. 2010;16(27):2988-97. Review.


Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.

Prosser GA, Copp JN, Syddall SP, Williams EM, Smaill JB, Wilson WR, Patterson AV, Ackerley DF.

Biochem Pharmacol. 2010 Mar 1;79(5):678-87. doi: 10.1016/j.bcp.2009.10.008. Epub 2009 Oct 21.


Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.

Wilson WR, Stribbling SM, Pruijn FB, Syddall SP, Patterson AV, Liyanage HD, Smith E, Botting KJ, Tercel M.

Mol Cancer Ther. 2009 Oct;8(10):2903-13. doi: 10.1158/1535-7163.MCT-09-0571. Epub 2009 Oct 6.


The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).

Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, Denny WA, Wilson WR, Patterson AV.

Cancer Gene Ther. 2007 Dec;14(12):953-67. Epub 2007 Nov 2.


Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR.

Clin Cancer Res. 2007 Jul 1;13(13):3922-32.

Supplemental Content

Loading ...
Support Center